Zealand Pharma A/S. PEG Ratio

Zealand Pharma A/S. (ZEAL) currently reports a PEG ratio of -27.02. That is below the Healthcare sector average of 4.93. Use the charts on this page to explore Zealand Pharma A/S.'s PEG ratio history and peer comparisons.

Zealand Pharma A/S.'s PEG ratio of -27.02 is lower than the Healthcare sector average of 4.93. That is roughly 647.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Zealand Pharma A/S.'s market price to a fundamental measure such as earnings, sales, or book value. At -27.02, ZEAL can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of -27.02, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 4.93. From there, open related valuation or income-statement pages for Zealand Pharma A/S., and consider following ZEAL for alerts when major investors trade the stock.

Zealand Pharma A/S. is classified in the Healthcare sector. On PEG ratio, it currently shows -27.02 versus a sector average near 4.93. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZEAL with unrelated industries.